DVA Valuation Metrics
DVA Stock Price Metrics
DVA Dividend Metrics
DVA Growth Rate Metrics
DVA Discounted Cash Flow Metrics
| Fair Value Price | $233.55 |
| Margin of Safety | 11.93% |
DVA Revenue Metrics
DVA PE Ratio Metrics
| PE Ratio | 20.99 |
| PE Ratio Avg TTM | 14.45 |
| PE Ratio Avg 3Y | 15.87 |
| Current VS TTM Avg | +45.25% |
| Current VS 3Y Avg | +32.25% |
| Current VS 5Y Avg | +41.48% |
DVA PS Ratio Metrics
| PS Ratio | 1.04 |
| PS Ratio Avg TTM | 0.82 |
| PS Ratio Avg 3Y | 0.91 |
| Current VS TTM Avg | +26.30% |
| Current VS 3Y Avg | +14.90% |
| Current VS 5Y Avg | +16.31% |
DVA PB Ratio Metrics
| PB Ratio | 99.53 |
| PB Ratio Avg TTM | 42.86 |
| PB Ratio Avg 3Y | 21.68 |
| Current VS TTM Avg | +132.24% |
| Current VS 3Y Avg | +359.03% |
| Current VS 5Y Avg | +492.14% |
DVA Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 9.63 |
| PFCF Ratio Avg TTM | 8.01 |
| PFCF Ratio Avg 3Y | 8.73 |
| Current VS TTM Avg | +20.26% |
| Current VS 3Y Avg | +10.34% |
| Current VS 5Y Avg | +9.90% |
DVA Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 99.63 |
| Debt/Equity Ratio Avg TTM | 55.08 |
| Debt/Equity Ratio Avg 3Y | 35.65 |
| Current VS TTM Avg | +80.88% |
| Current VS 3Y Avg | +179.45% |
| Current VS 5Y Avg | +283.34% |
DVA PEG Ratio Metrics
| PEG Ratio | 2.54 |
| PEG Ratio Avg TTM | 0.38 |
| PEG Ratio Avg 3Y | 0.35 |
| Current VS TTM Avg | +568.42% |
| Current VS 3Y Avg | +625.71% |
| Current VS 5Y Avg | +351.96% |
DVA FCF Yield
| FCF Yield | 10.38% |
| FCF Yield Avg TTM | 12.88% |
| FCF Yield Avg 3Y | 12.07% |
| Current VS TTM Avg | -19.41% |
| Current VS 3Y Avg | -14.03% |
| Current VS 5Y Avg | -14.04% |
DVA Earnings Yield
| Earnings Yield | 4.76% |
| Earnings Yield Avg TTM | 7.12% |
| Earnings Yield Avg 3Y | 6.45% |
| Current VS TTM Avg | -33.17% |
| Current VS 3Y Avg | -26.22% |
| Current VS 5Y Avg | -31.93% |
DVA EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 12.94 |
| Ev/Ebit Ratio Avg TTM | 11.79 |
| Ev/Ebit Ratio Avg 3Y | 13.02 |
| Current VS TTM Avg | +9.75% |
| Current VS 3Y Avg | -0.58% |
| Current VS 5Y Avg | -1.48% |
DVA EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 9.95 |
| Ev/Ebitda Ratio Avg TTM | 9.07 |
| Ev/Ebitda Ratio Avg 3Y | 9.40 |
| Current VS TTM Avg | +9.67% |
| Current VS 3Y Avg | +5.84% |
| Current VS 5Y Avg | +5.89% |
DVA EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.54 |
| Ev/Assets Ratio Avg TTM | 1.38 |
| Ev/Assets Ratio Avg 3Y | 1.35 |
| Current VS TTM Avg | +11.33% |
| Current VS 3Y Avg | +14.21% |
| Current VS 5Y Avg | +17.57% |
DVA EV/Sales Ratio Metrics
| Ev/Sales Ratio | 1.94 |
| Ev/Sales Ratio Avg TTM | 1.81 |
| Ev/Sales Ratio Avg 3Y | 1.84 |
| Current VS TTM Avg | +7.17% |
| Current VS 3Y Avg | +5.47% |
| Current VS 5Y Avg | +4.92% |
DVA Current Ratio Metrics
| Current Ratio | 1.29 |
| Current Ratio Avg TTM | 1.27 |
| Current Ratio Avg 3Y | 1.23 |
| Current VS TTM Avg | +1.18% |
| Current VS 3Y Avg | +4.45% |
| Current VS 5Y Avg | +2.79% |
DVA Quick Ratio Metrics
| Quick Ratio | 1.24 |
| Quick Ratio Avg TTM | 1.23 |
| Quick Ratio Avg 3Y | 1.19 |
| Current VS TTM Avg | +1.22% |
| Current VS 3Y Avg | +4.64% |
| Current VS 5Y Avg | +2.62% |
DVA ROIC Metrics
| ROIC | 10.58% |
| ROIC Avg 3Y | 9.48% |
| ROIC Avg 5Y | 9.31% |
| Current VS 3Y Avg | +11.57% |
| Current VS 5Y Avg | +13.58% |
| Current VS 10Y Avg | +25.60% |
DVA Return on Assets Metrics
| ROA | 4.27 |
| ROA Avg TTM | 4.84 |
| ROA Avg 3Y | 4.27 |
| Current VS TTM Avg | -11.87% |
| Current VS 3Y Avg | -0.06% |
| Current VS 5Y Avg | -6.33% |
DVA Return on Equity Metrics
| ROE | (114.70) |
| ROE Avg TTM | 329.18 |
| ROE Avg 3Y | 200.63 |
| Current VS TTM Avg | -134.84% |
| Current VS 3Y Avg | -157.17% |
| Current VS 5Y Avg | -169.66% |
DVA Net Profit Margin Metrics
| Net Profit Margin | 5.47% |
| Net Profit Margin Avg TTM | 6.39% |
| Net Profit Margin Avg 3Y | 5.83% |
| Current VS TTM Avg | -14.40% |
| Current VS 3Y Avg | -6.13% |
| Current VS 5Y Avg | -14.60% |
Last Updated: Monday, June 15, 2026
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez